acta de conferencia
"Biodistribution of the boron carriers boronophenylalanine (BPA) and/or decahydrodecaborate (GB-10) for Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases"
V.A. Trivillin, M.A. Garabalino, L.L. Colombo, S.J. González, R.O. Farías, A. Monti Hughes, E.C.C. Pozzi, S. Bortolussi, S. Altieri, M.E. Itoiz, R.F. Aromando, D.W. Nigg and A.E. Schwint
Proc. of the "15th International Congress on Neutron Capture Therapy" (15-ICNCT), Tsukuba, Japan, September 10-14, 2012. Ed. by A. Matsumura, T. Yamamoto, K. Nakai and H. Kumada
Appl. Radiat. Isot. 88 (2014) 94-98
Abstract
BNCT was proposed for the treatment of diffuse, non-resectable tumors in the lung. We performed boron biodistribution studies with 5 administration protocols employing the boron carriers BPA and/or GB-10 in an experimental model of disseminated lung metastases in rats. All 5 protocols were non-toxic and showed preferential tumor boron uptake versus lung. Absolute tumor boron concentration values were therapeutically useful (25-76 ppm) for 3 protocols. Dosimetric calculations indicate that BNCT at RA-3 would be potentially therapeutic without exceeding radiotolerance in the lung.
SUBGERENCIA TECNOLOGIA Y APLICACIONES DE ACELERADORES
